

Original Research Article

OXIDANT–ANTIOXIDANT STATUS AND RENAL FUNCTION IN WISTAR RATS AFTER ADMINISTRATION OF *Vernonia amygdalina* FRACTIONS IN STREPTOZOTOCIN INDUCED DIABETES MELLITUS

ABSTRACT

Diabetes mellitus is a group of metabolic diseases characterized by sustained hyperglycemia resulting from defects in insulin secretion, insulin action, or both. It accounts for about 3% of all deaths globally and affects all glucose utilizing tissue leading to severe complications. One third of diabetes patients eventual develops renal complications and is the major cause of end stage renal disease the pathogenesis of which has been associated to oxidative stress. An alternative approach in the management of diabetes has focused on the role of herbs. In this study, *Vernonia amygdalina* a tropical savanna herb was studied for its potent antioxidant property and its ameliorative effect on diabetic renal complication. 40 adult male Wistar rats were divided into eight groups (n=5) A-H. Fresh *Vernonia amygdalina* leaves were extracted and fractionated using four solvents of varying polarity. The extracts were further concentrated and reconstituted and was administered to the animals. Group A were used as control, groups B-H were induced diabetes with a single intravenous injection of 60mg/kg B.W. streptozotocin. Group B were induced with diabetes but left untreated, group C received metformin (50 mg/kg B.W.) while groups D-H received 300mg/kg B.W of crude *Vernonia* and the respective fractions of the plants. Laboratory analysis at the end of the analysis showed that the plant crude and fraction reduced the level of fasting blood glucose between 30 – 80%, increased serum catalase and superoxide dismutase level while decreasing malondialdehyde level. The plant caused significant reduction in serum creatinine level compared to the untreated diabetic groups and the control groups. The study shows that *Vernonia amygdalina* reduces oxidative stress by causing a balance in the oxidant – antioxidant level as well restores deranged renal function seen in diabetes mellitus.

INTRODUCTION

Diabetes mellitus is a group of metabolic diseases characterized by sustained hyperglycemia resulting from defects in insulin secretion, insulin action, or both. The incidence of diabetes has become a global pandemic affecting people of all race, nations, gender, works of life and social class with a global burden of 247 million in 2013 and an estimated global incidence of 438 million in 2030 (IDF, 2011). Diabetes accounts for 3.3% of all global deaths (WHO, 2014). Tropical countries in Asia and Africa have witnessed increasing risk and incidence of diabetes in recent times. This rise has been attributed to the adoption of a western diet and sedentary lifestyle. Irrespective of type, diabetic patient presents with a variety of signs and symptoms ranging from polyuria to skin manifestations such as tags and vitiligo. However, classical symptoms of diabetes include; Polyuria, polydipsia, fatigue, blurring of vision, weight loss, glycosuria and ketonuria (Vijan, 2010). The chronic hyperglycemia causes many of the major complications of diabetes, with long-term damage, dysfunction and failure of various organs, especially the eyes, kidneys, nerves, heart and blood vessels (DeFronzo, 1997). These latter effects of hyperglycaemia may result from oxidative stress.

Oxidative Stress and Tissue Damage in Diabetes

Oxidative stress results from increased content of reactive oxygen species (ROS) and/or reactive nitrogen species (RNS) above antioxidant levels. ROS include charged species such as superoxide and the hydroxyl radical and uncharged species such as hydrogen peroxide (Rosen *et al.*, 2001). There is evidence that oxidative stress which is a persistent imbalance between the production of highly reactive molecular species (chiefly oxygen and nitrogen) and the body's antioxidant defenses, leads to tissue damage in diabetes (Rosen *et al.*, 2001). Research shows that ROS formation is a direct consequence of hyperglycemia (Brownlee, 2001); Because of their ability to directly oxidize and damage DNA, protein, and lipid, ROS are believed to play a key direct role in the pathogenesis of late diabetic complications (Rosen *et al.*, 2001; Nishikawa *et al.*, 2000). In addition to their ability to directly inflict macromolecular damage, ROS can function as signaling molecules to activate a number of cellular stress-sensitive pathways that cause cellular damage, and are ultimately responsible for the late complications of diabetes.

The resultant effect of oxidative stress in tissues is progressive lipid peroxidation of lipids of cell membranes. Lipid peroxidation or reaction of oxygen with unsaturated lipids produces a wide variety of oxidation products. The main primary products of lipid peroxidation are lipid hydroperoxides (LOOH). Among the various aldehydes which can be formed as secondary products during lipid peroxidation, malondialdehyde (MDA), propanal, hexanal, and 4-hydroxynonenal (4-HNE) have been extensively studied by Esterbauer *et al.*, (1991). Malondialdehyde appears to be the most mutagenic product of lipid peroxidation. It is an end-product generated by decomposition of arachidonic acid and larger polyunsaturated fatty acids (PUFAs) (Esterbauer *et al.*, 1991), through enzymatic or non-enzymatic processes. Once formed MDA can be enzymatically metabolized or can react on cellular and tissular proteins or DNA to form adducts resulting in biomolecular damages. The body's antioxidant system checks and balances the activity of reactive oxygen species to prevent its harmful effect on tissues. Superoxide dismutase and catalase constitute part of the antioxidant defense mechanisms that maintain this balance.

Catalase an enzyme antioxidant found in nearly all living organisms exposed to oxygen catalyses the decomposition of hydrogen peroxide; (a harmful by-product of many normal metabolic processes) to water (Chelikani *et al.*, 2004). Catalase has the highest turnover number of enzymes, one catalase molecule can convert millions of molecules of hydrogen peroxide to water and oxygen each second (Goodsell, 2004). All known animals use catalase in every organ with particularly high concentrations occurring in the liver (Boon *et al.*, 2007). Superoxide Dismutase are enzymes that catalyses the dismutation of superoxide ion into oxygen and hydrogen peroxide. Thus, they are an important antioxidant defense in nearly all cells exposed to oxygen (McCord and Fridovich, 1988). There are three major families of superoxide dismutase, depending on the metal cofactor: Cu/Zn (which binds both copper and zinc), Fe and Mn (which binds iron or manganese) and Ni (which binds nickel) (Corpas *et al.*, 2006).

Diabetes and Renal Complication

The diabetic patient is at risk of serious large vessel disease in the kidneys, glomerular microvasculopathy which poses serious and predictable threat to the victim's longevity (Bangstad *et al.*, 1994). Diabetic nephropathy occurs in approximately one third of all type II diabetes (Rehman *et al.*, 2005) and diabetes has been identified as the major cause of end-stage renal disease (ESRD) around the world having enormous medical, social and economic consequences. Diabetes affects the kidney in stages; at the onset of diabetes, the kidney grows

large and the glomerular filtration rate (GFR) becomes disturbed. Most recent basic and clinical research has pointed toward sclerosis and kidney failure. Several mechanisms have been attributed to the development of diabetic nephropathy. Of scientific importance are the roles of renal glucose transporter (GLUT1) expression (Heilig, 2006), abnormalities of vasodilatation and generation of reactive oxygen species (ROS) mediated by endothelial derived nitric oxide (NO) (Dabla, 2010), suggesting linkage between vascular and metabolic abnormalities. Angiotensin II and aldosterone, interacting with pulse pressure and increased systolic blood pressure, activate NADP oxidase, which acts as mediator of oxidative stress. Sowers *et al.*, (2002) discussed the relationship between dyslipidemia and Chronic Kidney disease, hypothesizing that the mechanism of action of statins is an increase in endothelial NO synthase transcription via the phosphatidylinositol 3-kinase (PI3K) pathway and statin-induced inhibition of the mobilization of small molecular weight G-proteins. Also, Sowers suggested that the direct renin inhibitor aliskiren has similar benefits in renal disease to those of angiotensin receptor binders.

The inadequate cellular glucose utilization in diabetes leads to increased gluconeogenesis where protein and amino acid provide the substrate for new energy production increasing deamination of proteins and production of uric wastes such as urea and creatinine to be cleared off by the kidneys. Since the kidneys are the sites of excretion of metabolic wastes, renal complications especially in disease conditions are diagnosed in the laboratory as the ability of the kidney to clear off these metabolic wastes. A diagnostic criterion for renal function is the measurement of serum urea and creatinine levels. At all stages of renal insufficiency as seen in diabetic nephropathy, the serum creatinine is a much more reliable indicator of renal function than the blood urea nitrogen because the blood urea nitrogen is far more likely to be affected by dietary and physiologic conditions not related to renal function. However, the blood urea nitrogen and creatinine, taken together, are valuable screening tests in evaluating renal disease.

Herbal Remediation for Diabetes and its Complications

Several allotrophic medications have been used over the years to treat and manage diabetes, but the costs of such medications are exorbitant and they also have some side effects which reduce patient's compliance. Hence, recent attempts for the development of new antidiabetic therapy have focused on harnessing the medicinal potency of herbal plants (Zaidi, 1998). *Vernonia amygdalina* also known as bitter leaf, a tropical savanna shrub of the order *Asteraces* and family *Compositae* has attracted attention for its broad spectrum medicinal uses in the tropics. Several studies have evaluated the antidiabetic property (Okolie, 2008; Erasto *et al.*, 2007; Osinubi, 2007) of *Vernonia amygdalina*; its hypoglycaemic potency (Osinubi, 2007; Nwanjo, 2005) and its metabolic effect on various organ systems (Akah *et al.*, 2009; Iwalokun *et al.*, 2006). Also, *Vernonia amygdalina* ethanol extract was shown to possess antioxidant activity from free radical scavenging test by Ayoola *et al.*, (2008), its total flavonoid and phenolic contents was found to be correlated positively with total antioxidant activity of the plant. Phenolic compounds identified in *Vernonia amygdalina* can be grouped into flavonoides, tannins and caffeoyl quinic acid (Salawu and Akindahunsi, 2007). Flavonoids protect the cell as antioxidant against free radicals and reactive oxygen species (ROS).

It is against this backdrop that the present study aims at evaluating the hypoglycaemic potency of *Vernonia amygdalina*, investigate the antioxidant activity of *Vernonia amygdalina* and its fractions and the consequent effect on the renal complication in diabetes mellitus.

MATERIALS AND METHODS

CHEMICALS

Chemicals (analytical grade) used for this study were purchased from Rovet Scientific Ltd. 1, Wire Road, Benin city, Edo State. All the reagents for the assays were commercial kits and products of Randox Laboratories Ltd, Antrim, United Kingdom. Metformin (Glucophage) was purchased from a local Pharmacy in Abraka. The tablets were dissolved in distilled water to get the appropriate concentrations (0.5gm/100g) that were administered to the rats, using the formula: rat dose = (human dose/average BW) x 7. Streptozotocin (STZ) (Batch 1378), Address: Sigma. Aldrich Co.3050 Spruce Street St. Louis Mo 63103 U.S.A 314-771-5765, Acetic Acid (Batch – 70419322), H₂SO₄ SL 7041419322, E .Merk, Darmstadt 2.5l, Weigh: 1.05lg, Ethyl Acetate (1502 batch 1356o517) Gato Perez, 33-P.1. Masden Gsa 08181sentmenat Spam. Shelf Life 5/2017, N-Butanol, Guangdong Guanghua Sci-Tech Co., Ltd. Shatou, Guangdong, China, 515000, Benzene (Batch No. 704 L419322). Gato Perez, 33-P.1. Masden Gsa 08181sentmenat Spam. Shelf Life 5/2017,

METHODS

Source of *Vernonia amygdalina*

Fresh *Vernonia amygdalina* leaves were collected at the staff quarter, located at Site III, Delta State University Abraka, Delta State, Nigeria and was authenticated in Forestry Research Institute of Nigeria, Ibadan, with herbarium number; FHI 110336. The plants were transported to Emma-Maria Scientific and Research Laboratory Abraka for extraction.

Extraction Procedure

Vernonia amygdalina leaves were air-dried, crushed and soaked in ethanol for 48 hours after which the ethanolic extract was sieved out and allowed to dry. The resultant ethanol-free juice was subjected to a serial liquid – liquid fractionation method using solvents of varying polarity from non-polar to highly polar following Ekam *et al.*, (2013). Solvents used include; Benzene, Chloroform, Ethyl acetate and Butanol. The fractions gotten were: Benzene Fraction, Chloroform fraction, Ethyl acetate fraction and Butanol fraction. Fractionation procedure was as follow: 200ml of the crude extract of bitter leave was measured using a measuring cylinder into a 500ml separating funnel, held using a retort stand and clamp. 200ml of benzene was added to it, shook properly and allowed to stand 30 minutes. The mixture separated into two layers; one layer containing benzene soluble constituents of *Vernonia amygdalina* which was collected into a beaker, and the other layer containing non benzene soluble residue. The resultant residue was allowed to air dry to remove any trace of benzene in the residue. After drying, 200ml of the residue was measured into a separating funnel and 200ml of chloroform was added to it, shook properly and allowed to stand for separation. The mixture separated in two layers as above (Chloroform soluble constituents and non-chloroform soluble residue). The non-chloroform soluble phase was collected, allowed to air dry and then put into another separating funnel and further fractioned using Ethyl acetate; the mixture separated into two phases and collected as above. 200ml of the residue from ethyl acetate fractionation was allowed to air-dry and further fractioned using 200ml of butanol and allowed to stand, separate and the fraction collected. The fractions gotten were allowed to dry to powder and identified by the solvent used for the extraction. The extracts were then reconstituted using water for water soluble extracts and Tween-80 (a placebo) for lipid soluble extracts.

Handling of Animals

After receiving approval from the Faculty bioethics committee for the use of laboratory animals for research, forty (40) adult male *Wistar* rats, weighing between 100-200g were used in this research. The animals were bred and purchased from the Emma-Maria Laboratory Animal unit, Abraka, Delta State and transported in plastic basket to the College of Health Sciences Laboratory Animal Facility, Delta State University, Abraka and housed under standard laboratory conditions in stainless steel cages, supplied with clean drinking water and fed *ad libitum* with standard commercial pelleted feed (Vital feed, UAC, Lagos).

Induction and Treatment

Diabetes was induced using Streptozotocin dissolved in sodium citrate buffer. Fasting blood glucose levels of the animals were checked after an overnight fast prior to induction. Streptozotocin was prepared by dissolving 2g of Sodium Citrate in 100ml of water to yield 0.1mole of citrate buffer; 0.6g of Streptozotocin was dissolved in 10ml of citrate buffer to yield 60mg of Streptozotocin. The resultant solution was injected into the animals based on their body weight, through the lateral tail vein at 60mg/kg B.W. Fasting blood glucose level was assessed using ACCUCHEK active blood glucometer, 72hours after induction. A 50% increase in pre-induction fasting Blood glucose level was considered to be diabetic.

Treatment group

The study comprised of 40 animals divided in eight groups (n=5) and were treated as follow;

- Group A: Non diabetic, untreated (Control) group.
- Group B: Untreated diabetic group (Negative control).
- Group C: Diabetic group treated with 50mg/kg/day of Metformin
- Group D: Diabetic group treated with 300mg/kg/day of Crude *Vernonia amygdalina*
- Group E: Diabetic group treated with 300mg/kg/day of Benzene fraction
- Group F: Diabetic group treated with 300mg/kg/day of Chloroform fraction
- Group G: Diabetic group treated with 300mg/kg/day of Ethyl acetate fraction
- Group H: Diabetic group treated with 300mg/kg/day of Butanol fraction

Observation

The fasting blood glucose levels of the experimental animals were monitored weekly to determine the progression of the disease and the effect of the extract on the blood glucose level.

Sacrificing of animals and Sample Collection

At the end of the experiment, the animals were subjected to an overnight fast, and their final fasting blood level checked. The animals were sacrificed by cervical dislocation and a laparotomy was carried out on each animal to access the internal organs; blood was collected by cardiac puncture, using 5ml syringes and 21G needle into plain blood sample containers for biochemical analysis. Biochemical analysis was carried out on the samples collected to determine the level of antioxidant activities, lipid peroxidation and renal function as shown below;

Assessment of Kidney Function

Urea (Colorimetric Method)

Urea content of the serum samples was estimated by means of an automated analyzer, Blood Urea Analyzer, Beckman Coulter Inc., USA. The analysis procedure required a set up of

reagents, Hichem kit of reagents for blood urea nitrogen analyzer. The kit is supplied by Elan Diagnostics, USA (Adekomi, 2010).

Creatinine (Colorimetric Method)

Creatinine Analyzer-2 (Beckman Coulter Inc., USA) in combination with a specific kit of reagents (Hichem Creatine Pak, Elan Diagnostics, USA) was employed to calculate creatinine content of the serum samples (Adekomi, 2010).

Assay of Enzymatic Antioxidants

Assay of Catalase (CAT) activity

 Catalase activity was measured according to the method of Aebi (1983). 0.1 ml of the homogenates (supernatant) was pipetted into cuvette containing 1.9 ml of 50mM phosphate buffer, pH 7.0. Reaction was started by the addition of 1.0 ml of freshly prepared 30% (v/v) hydrogen peroxide (H₂O₂). The rate of decomposition of H₂O₂ was measured spectrophotometrically from changes in absorbance at 240nm. Activity of enzyme was expressed as units /mg protein.

Assay of Superoxide Dismutase (SOD) Activity

Superoxide dismutase activity was measured according to the method of Misra and Fridovich (1972) and adopted by Isamah, *et al*, (1994). The principle of the assay was based on the ability of SOD to inhibit the autooxidation of epinephrine by superoxide radical (O₂⁻). Briefly, the reaction mixture contained 0.2ml of the Stomach suspension; 2.5ml of 0.05M carbonate buffer pH 10.2 was added. The reaction will start by adding 0.3ml freshly prepared 0.3M adrenaline. This was mixed by inversion. A reference cuvette containing 2.5ml of the buffer and 0.2ml of water and 0.3ml of the substrate (epinephrine). The increase in absorbance was monitored at 480nm every 30seconds for 150seconds. Percentage inhibition of SOD activity will then be calculated: One unit of SOD was defined as the amount of enzyme required to inhibit the autooxidation of epinephrine by 50% under the specific conditions. It was expressed as u/mg protein.

Estimation of Lipid Peroxidation (Malondialdehyde)

Lipid peroxidation was estimated spectrophotometrically by thiobarbituric acid reactive substances TBARS method of Buege and Aust (1978). A principal component of TBARS being malondialdehyde (MDA), a product of lipid peroxidation. 0.1 ml of the serum was treated with 2ml of (1:1:1 ratio) TBA-TCA-HCl reagent (thiobarbituric acid 0.37%, 0.25 N HCl and 15% TCA) and placed in water bath for 15 min, cooled. The absorbance of clear supernatant was measured against reference blank at 535nm. Concentration was calculated using the molar absorptivity of malondialdehyde which is 1.56 x10⁵ M⁻¹ cm⁻¹ and expressed as nmol/mg protein.

RESULTS

Effect of *Vernonia amygdalina* on the Fasting Blood Glucose Level of Experimental Rats

The effect of administration of *Vernonia amygdalina* and its fractions on the fasting blood glucose level (FBGL) of normoglycaemic, diabetic rats and the percentage FBGL change is represented in the figure 1 below;




Fig. 1: Showing the effects of *Vernonia amygdalina* on the fasting blood glucose level in STZ-induced diabetic experimental rats expressed as Mean±S.E.M. (a) Significant increase, (b) Significant decrease when compared with Control. (*) Significant increase (#), significant decrease when compared with diabetic control

From the above figure, *Vernonia amygdalina* and its fraction caused a significant decreased in the final blood glucose level with the highest percentage decrease observed in groups treated with crude extract, ethyl acetate and chloroform fractions of the plant.

Effect of *Vernonia amygdalina* on the Level of Antioxidant Enzymes

The effect of administration of *Vernonia amygdalina* and its fractions on the level of catalase and superoxide dismutase in normoglycaemic, diabetic rats is represented in the figure 2 below;




Fig. 2: Showing the effects of *Vernonia amygdalina* on the level of superoxide dismutase and catatalse activity in STZ-induced diabetic experimental rats expressed as Mean±S.E.M. (a) significant increase, (b) Significant decrease when compared with Control. (*) Significant increase (#), significant decrease when compared with diabetic control

From the above figure, *Vernonia amygdalina* and its fraction caused a significant increase in the level of superoxide dismutase activity in groups treated with crude extract, ethyl acteate and benzene fractions of the plant. While only crude extract caused a slight increase in catalase activity.

Effect of *Vernonia amygdalina* on the Level of Lipid Peroxidation

The effect of administration of *Vernonia amygdalina* and its fractions on the level of malondialdehyde in normoglycaemic, diabetic rats is represented in the figure 3 below;




Fig. 3: Showing the effects of *Vernonia amygdalina* on the level of malondialdehyde in STZ-induced diabetic experimental rats expressed as Mean±S.E.M. (a) significant increase, (b) Significant decrease when compared with Control. (*) Significant increase (#), significant decrease when compared with diabetic control

From the above figure, *Vernonia amygdalina* and its fraction caused a significant decreased in the level of malondialdehyde in groups treated with crude extract, ethyl acetate and chloroform fractions of the plant.

Effect of *Vernonia amygdalina* on Renal Function

The effect of administration of *Vernonia amygdalina* and its fractions on the level of blood urea nitrogen and serum creatinine in normoglycaemic and diabetic rats is represented in the figure 4 below;




Fig. 4: Showing the effects of *Vernonia amygdalina* on the level of malondialdehyde in STZ-induced diabetic experimental rats expressed as Mean±S.E.M. (a) significant increase, (b) Significant decrease when compared with Control. (*) Significant increase (#), significant decrease when compared with diabetic control

From the above figure, the level of blood urea nitrogen was not improved by administration of *Vernonia amygdalina* and its fraction, while serum creatinine level was significantly decreased in rat groups treated with crude extract, butanol and chloroform fractions of the plant.

DISCUSSION

Diabetes affects principally the metabolism of glucose resulting in hyperglycaemia. All antidiabetic therapy is targeted at restoring euglycaemia, that is a plasma glucose level close or around physiological ranges. In this study, *Vernonia amygdalina* and its fractions caused significant reduction in fasting blood glucose level at the end of the experiment, with the crude extract causing 81.5% reduction while administration of ethyl acetate and chloroform fractions caused 69.7%, and 65.9% reduction respectively, higher than that of metformin which showed 36.5% reduction in fasting blood glucose level of diabetic rats. This conforms to an earlier study by Nwanjo, (2005) on the purported the hypoglycaemic property of *Vernonia amygdalina*. The result of this study shows that administration of *Vernonia amygdalina* and fractions caused a significant decrease in fasting blood glucose level similar to Ekam *et al.*, (2013) who observed that fractions from *Vernonia amygdalina* significantly reduced blood glucose levels of diabetic rats in similar percentages. This confirms the hypoglycaemic property of the plant and its fractions. The hypoglycaemic property of the plant found to be highest in the crude extracts may be attributed to the presence of known hypoglycaemic phytochemical constituents of the herb including but not restricted to sesquiterpene lactones and steroid glucosides (Babalola *et al.*, 2001; Koshimizu *et al.*, 1994). It has also been suggested that bitter principle as seen in aloes may stimulate synthesis and/or release of insulin from the beta-cells of Langerhans (Ajabnoor, 1990). *Vernonia amygdalina* contains both sesquiterpene lactones and bitter principle, may therefore act through stimulation of synthesis and/or release of insulin from the beta-cells of the pancreatic islets as suggested by Atangwho *et al* (2014).

Oxidant – antioxidant balance and lipid peroxidation level can be used to predict the severity of diabetes induced renal complications. Antioxidants enzymes such as Superoxide dismutase and Catalase dependently act in the metabolic pathways that involve free radicals scavenging. In diabetes mellitus, this balance is altered in favour of the oxidants resulting in organ complications as seen in the untreated diabetic group. The restoration of this balance, which is the increase in antioxidants (SOD and Catalase) and consequent decrease in lipid peroxidation (MDA) was observed to be prominent after administration *Vernonia amygdalina* crude extract and its ethyl acetate fraction. This is in line with the finding of Ogunlade *et al.*, (2012) who observed a similar increase in the activity of antioxidant enzymes and decreased MDA level with administration of *Vernonia amygdalina* extract to alcohol induced toxicity in rats. This suggests the potent antioxidant capacity of *Vernonia amygdalina* and its fraction capable of restoring oxidant – antioxidant balance either by improving endogenous antioxidants or contributing its own antioxidant constituent to assist in scavenging free radicals in the body.

The kidneys maintain optimum chemical composition of body fluid by acidification of urine and removal of metabolic wastes such as urea, uric acid, and creatinine. The inadequate cellular glucose utilization in diabetes leads to increased gluconeogenesis. Proteolysis and hepatic amino acid deposition feed the liver for gluconeogenesis which constitutes deamination of proteins and production of uric wastes such as urea and creatinine to be cleared off by the kidneys. However, in diabetic nephropathy, the excretory efficiency of the kidney nephrons has been compromised causing the concentration of these metabolites to accumulate and increase in blood (Jaspreet *et al.*, 2000). In this study, blood urea nitrogen levels of all diabetic rats were seen to be increased as compared to the non diabetic rats. Administration of *Vernonia amygdalina* extract and fractionates showed no significant reversal of this elevated values in the diabetic rats. Blood creatinine levels on the other hand were reduced on administration of the plant extract and fractionate to diabetic rats. Several factors such as food type, physical activities

and starvation may influence urea level while making it a non-specific diagnostic assay. Creatinine levels on the other hand are more specific and serve as better diagnostic tool for renal competence (Loeb, 1991). This suggests a restoration of renal function in diabetic rats. Similar renal restoration capacity was reported by Atangwho *et al.*, (2007).

CONCLUSION

This study has demonstrated the ameliorative property of *Vernonia amygdalina* on both the kidney as well as plasma glucose. The nephritic derangement frequently seen in diabetes mellitus which has been attributed to the activity of free radicals was ameliorated by the restoration of oxidant-antioxidant balance with administration of *Vernonia amygdalina*.

REFERENCES

- Adekomi D. A., (2010) "Madagascar Periwinkle (*Catharanthus roseus*) Enhances Kidney and Liver Functions in Wistar Rats," *International Journal of Biomedical and Health Sciences*, **6**(4):245-254.
- Aebi H. (1983) Catalase in Methods of Enzymatic Analysis ed. H.U. Bergmeyer, 3rd ed. Weinheim: *Verlag Chemie*; 273-286.
- Akah, P. A.; Alemji, J. A.; Salawu, O. A.; Okoye, T. C. and Offiah, N. V. (2009): Effects of *Vernonia amygdalina* on Biochemical and Hematological Parameters in Diabetic Rats. *Asian Journal of Medical Sciences*, **1**(3): 108-113.
- Atangwho I.J., Ebong P.E., Eteng, M.U., Eyong E.U., Obi, A.U. (2007), Effect of *Vernonia amygdalina* Del leaf on kidney function of diabetic rats. *International journal of pharmacology*; **3**(2):143-148
- Ayoola GA, Coker HAB, Adesegun SA, Adepoju-Bello AA, Obaweve K, Ezennia EC, Atangbayila TO (2008). Phytochemical screening and antioxidant activities of some selected medicinal plants used for malaria therapy in Southwestern Nigeria. *Trop. J. Pharm. Res.*, **7**:1019-1024
- Babalola OO, Anetor JI, Adeniyi FA (2001): Amelioration of carbon tetrachloride-induced hepatotoxicity by terpenoid extract from leaves of *Vernonia amygdalina*. *Afr J Med Med Sci*, **30**:91-93.
- Bangstad H.J., Osterby R, Daahl-Jorgensen K., Beg K.J, Hartman A, Hanssen KF. (1994) improvement of blood glucose control in IDDM patients retard the progression of morphological changes in early diabetic nephropathy. *Diabetologia*. **37**:483-490.
- Bauer JH, Brooks CS, Burch RN. (1982). Renal function studies in man with advanced renal insufficiency. *Am J Kidney Dis.*; **11**:30-35.
- Boon EM, Downs A, Marcey D. "Catalase: H₂O₂: H₂O₂ Oxidoreductase". Catalase Structural Tutorial Text.
- Brownlee M (2001): Biochemistry and molecular cell biology of diabetic complications. *Nature* **414**:813-820,
- Chelikani P, Fita I, Loewen PC (2004). "Diversity of structures and properties among catalases". *Cellular and Molecular Life Sciences* **61**(2):192-208.

- 416 Coresh J, Astor BC, Greene T, Eknoyan G, Levey AS. Prevalence of chronic kidney disease and
417 decreased kidney function in the adult US population: Third National Health and Nutrition
418 Examination Survey. *Am J Kidney Dis* 2003; 41:1-12
- 419 Corpas FJ, Fernández-Ocaña A, Carreras A, Valderrama R, Luque F, Esteban FJ, Rodríguez-
420 Serrano M, Chaki M, Pedrajas JR, Sandalio LM, del Río LA, Barroso JB (2006). "The
421 expression of different superoxide dismutase forms is cell-type dependent in olive (*Olea*
422 *europaea* L.) leaves". *Plant and Cell Physiology* 47(7): 984–994.
- 423 Dabla P.K. (2010). Renal function in diabetic nephropathy *World J Diabetes*; 1(2): 48-56
- 424 DeFronzo RA: Pathogenesis of type 2 diabetes: metabolic and molecular implications for
425 identifying diabetes genes. *Diabetes Review* 5:177–269, 1997
- 426 Ekam V. S., Ebong P. E., Johnson J. T., Dasofunjo, K (2013). Effect of Activity Directed
427 Fractions of *Vernonia amygdalina* on Total Body Weight and Blood Glucose Levels of Diabetic
428 Wistar Albino Rats. *International Journal of Science and Technology* 2(1):153-157
- 429 Erasto P., Grierson D. S., Afolayan A. J. (2007). Evaluation of Antioxidant activity and the Fatty
430 acid profile of the leaves of *Vernonia amygdalina* growing in South Africa. *Food Chemistry*
431 **104**:636-642.
- 432 Esterbauer H, R. J. Schaur, and H. Zollner, (1991), "Chemistry and Biochemistry of 4-
433 hydroxynonenal, malonaldehyde and related aldehydes," *Free Radical Biology and Medicine*,
434 **11**(1) 81–128.
- 435 Goodsell DS (2004). "Catalase". Molecule of the Month. *RCSB Protein Data Bank*.
- 436 Heilig CW, Brosius FC (2006) 3rd, Cunningham C. Role for GLUT1 in diabetic
437 glomerulosclerosis. *Expert Rev Mol Med*; 8: 1-18
- 438 Hill JM, Zalos G, Halcox JP, Schenke WH, Waclawiw MA, Quyyumi AA, Finkel T. (2003)
439 Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. *N Engl J*
440 *Med*; **348**: 593-600
- 441 International Diabetes Federation, (2011); Diabetes Atlas. 4th edition Elsevier publishing, Delhi
442 India.
- 443 Isamah, G.K., Renner, J.K., Akintonwa, A., Ibrahim, M., Osibogun, R. and Coker, H.A.B.,
444 (1995) Enzyme modulation and toxicology potential of artemisinin derivation, arthemether on
445 prolong administration in rats. *West Afri. J. Pharmacol Drug Res.*; **11**: 9-22.
- 446 Iwalokun BA, Efedede BU, Alabi-Sofunde JA, Oduala T, Magbagbeola OA, Akinwande AI
447 (2006). Hepatoprotective and antioxidant activities of *Vernonia amygdalina* on acetaminophen-
448 induced hepatic damage in mice. *J. Med. Food*; 9:524–530.
- 449 Jaspreet V, Sivakami S, Shahani S, Suthar AC, Banaralika MM, Biyani MK (2000):
450 Antihyperglycemic effect of three extract from *Monordia charantia*. *J Ethnopharmacol*,
451 **88**:107–111.
- 452 Loeb WF (1999) The non-human primate In The clinical chemistry of laboratory animals (Taylor
453 & Francis, Philadelphia), 145–162.

- 454 McCord JM, Fridovich I (1988). "Superoxide dismutase: the first twenty years (1968-1988)".
455 *Free Radical Biology and Medicine* 5(5-6): 363-369.
- 456 Misra HP, Fridovich I. (1972) The role of superoxide anion in the autoxidation of epinephrine
457 and a simple assay for superoxide dismutase. *J Biol Chem.*; **247**(10):3170–3175
- 458 Nishikawa T, Edelstein D, Brownlee M (2000): The missing link: a single unifying mechanism
459 for diabetic complications. *Kidney Int* 58:26–30
- 460 Nwanjo H.U. (2005): Efficacy of aqueous leaf extract *Vernonia amygdalina* on plasma lipoprotein
461 and oxidative status in diabetic rats models; *Nature*. **20**:39-42.
- 462 Okolie UV, Okeke CE, Oli JM, Ehiemere IO (2008). Hypoglycemic indices of *Vernonia*
463 *amygdalina* on postprandial blood glucose concentration of healthy humans.*African Journal of*
464 *Biotechnology*, **7**: 4581-4585.
- 465 Osinubi AAA (2007). Effects of *Vernonia amygdalina* and chlorpropamide on blood
466 glucose.*Medical Journal Islamic World Academic Sciences*, **16**: 115-119.
- 467 Rehman A, Zamir S, Bhatti A, Jan SS, Ali S, Wazir F. (2012) Evaluation of albuminuria, total
468 plasma proteins and serum albumin in diabetics. *Gomal J Med Sci*; **10**:198-200.
- 469 Rosen P, Nawroth PP, King G, Moller W, Tritschler HJ, Packer L: The role of oxidative stress in
470 the onset and progression of diabetes and its complications: a summary of a Congress Series
471 sponsored by UNESCOMCBN, the American Diabetes Association, and the German Diabetes
472 Society. *Diabetes Metab Res Rev* 17:189–212, 2001
- 473 Salawu SO, Akindahunsi AA (2007).Protective effect of some tropical vegetables against CCl4–
474 induced hepatic damage.*Journal of Medicinal Food*, **10**: 350-355.
- 475 Sowers JR. (2002) Hypertension, angiotensin II, and oxidative stress. *N Engl J Med*; **346**: 1999-
476 2001
- 477 Vijan, S (2010). "Type 2 diabetes". *Annals of internal medicine* 152 (5): 15–31.
- 478 World Health Organization (WHO, 2014.). Global Health Estimates: Deaths by Cause, Age, Sex
479 and Country, 2000-2012. Geneva.
- 480 Zaidi SH (1998).Existing indigenous medicinal plants resources of Pakistan and their prospect
481 for utilization.*Pakistan Forest Journal*, **48**(2) 5-7